Elyse Stock - Jan 10, 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
Chief Medical Officer
Signature
/s/ George Clark, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Jan 10, 2022
Transactions value $
$0
Form type
4
Date filed
1/12/2022, 08:10 PM
Previous filing
Jan 7, 2022
Next filing
Oct 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +937 +21.12% $0.00 5.37K Jan 10, 2022 By Spouse
holding BHVN Common Shares 11.1K Jan 10, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise $0 +937 +93700% $0.00 938 Jan 10, 2022 Common Shares 937 By Spouse F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F2 The reporting person was granted 3,750 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date.
F3 Not applicable.